Strategic Initiative

Slingshot members are tracking this corporate initiative:

DURECT (DRRX) and Gilead (GILD) Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Source Link:: https://investors.durect.com/news-releases/news-release-details/durect-and-gilead-enter-license-agreement-long-acting-injectable?field_nir_news_date_value[min]=2019

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

100%

DRRX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Durect will grant Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology. Gilead also received exclusive access to the SABER® platform for HIV and Hepatitis B Virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV.

https://investors.du...

Additional Relevant Details
Under the terms of the agreement, Gilead will make an upfront payment to DURECT of $25 million, with the potential for up to an additional $75 million in development and regulatory milestones, up to an additional $70 million in sales based milestones, as well as tiered royalties on product sales. Gilead has the exclusive option to license additional SABER-based products directed to HIV and HBV for an additional $150 million per product in upfront, development, regulatory and sales based milestones as well as tiered royalties on sales.

https://investors.du...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Jul 22, 2019

Projected Implementation:

Q3, 2019

Relevance Tracked Until:

Q4, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords License Agreement, Hiv, Investigational New Drug, Saber